Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolelsimab
- Development stage
- Phase 4
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Tolelsimab is a recombinant humanized monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, it prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, thereby increasing the clearance of low-density lipoprotein cholesterol (LDL-C) from the blood. Developed by Innovent Biologics, it was approved by the National Medical Products Administration (NMPA) in China in August 2023 for the treatment of primary hypercholesterolemia and mixed dyslipidemia. The drug is also being evaluated in clinical trials for its impact on coronary atherosclerotic plaque progression and epicardial adipose tissue in patients undergoing coronary artery bypass grafting (CABG).
- Brand names
- SINTBILO
- Other names
- tolelsimab
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on tolelsimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolelsimab.